


Amendments to the Claims

The following listing of claims replaces all prior listings and version of claims in this application.

1. (Previously Presented) A compound of Formula I:



Formula I

wherein:

R_1 and R_2 are independently selected from the group consisting of hydrogen, a lower alkyl group, a lower alkoxy group, substituted or unsubstituted phenyl group, a lower alkyl substituted with at least one substituent selected from the group consisting of a phenyl group, a halogen, hydroxyl, thiol, nitro, cyano, or amino group; m and n are each independently 0-3;

X is selected from the group consisting of SO_2-NH , S and O ;

M represents substituted or unsubstituted alkylene of 1-4 carbon atoms;

Y is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide;

Z is $Arg-Pro-Arg-R_4-R_5-R_6-R_7$;

R_4 , R_5 , and R_6 are each independently selected from the group consisting of threonine, serine, glutamic acid allyl ester, homocitrulline, lysine, methionine, norleucine, ornithine, arginine, glycine, diaminopropionic acid, diaminobutyric acid, $GlyNH_2$, and alanine; or are an N^α - ω -functionalized derivative of an amino acid selected from the group of glycine, alanine and tyrosine;

R_7 is selected from the group consisting of phenylalanine, homoleucine, norleucine, glutamic acid allyl ester;

W may be absent so that Y is connected to L or R₄, or W is N-(8-sulfonamide-5-isoquinoline) ethylenediamine; and

L may be absent so that W (if present) or Y is connected to R₄, or L is selected from the group consisting of glycine, β -alanine, phenylalanine, aminobutyric acid and aminopentanoic acid and connects W (if present) or Y with R₄.

2. (Previously Presented) The compound of claim 1 wherein, in Formula I:

R₁ and R₂ are independently selected from the group consisting of methyl, ethyl, ethoxy and dimethylamine;

m and n are each 1;

M represents substituted or unsubstituted alkylene of 2 carbon atoms; and

Y is selected from the group consisting of amide and amine.

Claims 3 to 6. (Cancelled)

7. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Thr-Glu-(bAla-5-mercaptoaminopropyl-isoquinoline)-Ser-Phe (SEQ ID NO: 3).

8. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Thr-Glu-(5-mercaptoaminopropyl-isoquinoline)-Ser-Phe (SEQ ID NO: 4).

9. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Orn-Glu-(5-aminoethylsulfonamide-isoquinoline)-Ser-Phe (SEQ ID NO: 5).

10. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Nva-Glu-(5-mercaptoaminopropyl-isoquinoline)-Ser-Phe (SEQ ID NO: 6).

11. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Nle-Glu-(5-mercaptoaminopropyl-isoquinoline)-Ser-Phe (SEQ ID NO: 7).

12. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Orn-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Hol (SEQ ID NO: 8).

13. (Previously Presented) The compound according to claim 1 wherein the compound comprises:

Arg-Pro-Arg-Nle-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Phe (SEQ ID NO: 9).

14. (Currently Amended) The compound according to claim 1 wherein the compound ~~comprise~~ comprises:

Arg-Pro-Arg-Nle-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Hol (SEQ ID NO: 10).

15. (Original) A pharmaceutical composition comprising as an active ingredient a compound according to claim 1, and a pharmaceutically acceptable diluent or carrier.


16. (Original) A protein kinase inhibitor comprising as an active ingredient a compound according to claim 1, and a pharmaceutically acceptable diluent or carrier.

17. (Previously Presented) A method of treatment of diabetes, hemorrhagic shock, or inflammatory disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

18. (Cancelled)

19. (Cancelled)

20. (Currently Amended) A compound of Formula I:



Formula I

wherein:

[[R1]] R_1 and [[R2]] R_2 are independently selected from the group consisting of hydrogen, a lower alkyl group, a lower alkoxy group, substituted or unsubstituted phenyl group, a lower alkyl substituted with at least one substituent selected from the group consisting of a phenyl group, a halogen, hydroxyl, thiol, nitro, cyano, or amino group; m and n are each independently 0-3;

X is selected from the group consisting of [[S02]] $\text{SO}_2\text{-NH}$, S and O;

M represents substituted or unsubstituted alkylene of 1-4 carbon atoms;

Y is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide;

W is absent or is selected from the group consisting of substituted or unsubstituted alkylene, aliphatic, aromatic or heterocyclic moiety, of 1-18 carbon atoms;

L is absent or is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide; and

Z is a peptide or peptidomimetic moiety comprising one of the following sequences:

Arg-Pro-Arg-Thr-Glu-Ser-Phe (SEQ ID NO: 3);

Arg-Pro-Arg-Thr-Glu-Ser-Phe (SEQ ID NO: 4);

Arg-Pro-Arg-[[O3m]] O^m -Glu-Ser-Phe (SEQ ID NO: 5);

Arg-Pro-Arg-Nva-Glu-Ser-Phe (SEQ ID NO: 6);

Arg-Pro-Arg-Nle-Glu-Ser-Phe (SEQ ID NO: 7);

Arg-Pro-Arg-[[O3m]] O^m -Glu-Dab-Hol (SEQ ID NO: 8);

Arg-Pro-Arg-Nle-Glu-Dab-Phe (SEQ ID NO: 9); or

Arg-Pro-Arg-Nle-Glu-Dab-Hol (SEQ ID NO: 10); and wherein Y, W if present, or L if present are linked to the Glu residues of the sequences.

21. (Previously Presented) A pharmaceutical composition comprising as an active ingredient a compound according to claim 20, and a pharmaceutically acceptable diluent or carrier.

22. (Previously Presented) A protein kinase inhibitor comprising as an active ingredient a compound according to claim 20, and a pharmaceutically acceptable diluent or carrier.

23. (Previously Presented) A method of treatment of diabetes, hemorrhagic shock, or inflammatory disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 20.

24. (Cancelled)